• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

byOctavio ViramontesandAliya Ramjaun
October 12, 2018
in Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Metformin use may decrease risk of osteoarthritis development

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

Glucagon-like peptide-1 (GLP-1) potentiates the release of insulin from pancreatic beta cells in a glucose-dependent manner. While pharmacologic studies have shown that GLP-1 delays gastric emptying, reduces appetite, decreases food intake, and therefore, contributes to improved glucose homeostasis and bodyweight, some patients fail to achieve glycemic and bodyweight targets. LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Similar to GLP-1, GIP is a potent stimulator of glucose-dependent insulin secretion. In this double-blind randomized phase 2 study, 318 patients with inadequately controlled type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks to assess the efficacy and safety of co-stimulation of the GLP-1 and GIP receptor compared to placebo or selective stimulation of GLP-1 receptors with dulaglutide in patients with poorly controlled type 2 diabetes. Researchers found that at 26 weeks, the effect of LY3298176 on change in HbA1c was dose-dependent and did not plateau; the mean change from baseline in HbA1c with LY3298176 was -1.06% in the 1 mg group, -1.73% for the 5 mg group, -1.89% for the 10 mg group, and -1.94% for 15 mg group, as compared to -0.06% in the placebo group. This corresponded to mean differences of -1.00% (-1.22% to -0.79%) for 1 mg,
-1.67% (-1.88% to -1.46%) for 5 mg, -1.83% (-2.04% to -1.61%) for 10 mg, and -1.89% (-2.11% to -1.67%) for 15 mg.  Posterior mean differences for change in HbA1c were also significantly different in the 5 mg (-0.52%), 10 mg (-0.67%) and 15 mg (-0.73%) intervention groups when compared to patients that received dulaglutide. At 26 weeks of follow-up, 33-90% of patients treated with LY3298176 achieved a HbA1c target <7.0% compared to 52% of patients in the dulaglutide group and 12% of patients from the placebo group. In addition, 14-71% of those treated with LY3298176 achieved the weight loss target of at least 5% as compared to 22% of patients in the dulaglutide group and 0% of patients in the placebo group. The 12-week outcomes were like those at 26 weeks for all secondary outcomes.  Gastrointestinal events (nausea, diarrhea, and vomiting) were the most common treatment-emergent adverse events in the intervention groups. This study therefore indicates that this dual GIP and GLP-1 receptor agonist shows better efficacy with regard to glucose control and weight loss than dulaglutide and may thus represent a new treatment option in the management of type 2 diabetes.

Click to read the study in The Lancet

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetes
Previous Post

Quick Take: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomized, placebo-controlled trial 

Next Post

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

RelatedReports

Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

Metformin use may decrease risk of osteoarthritis development

March 30, 2023
Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

March 21, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

March 7, 2023
Next Post
Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

Quick Take: Single-dose versus 7-day-dose metronidazole (Flagyl) for the treatment of trichomoniasis in women: an open-label, randomized controlled trial

Tramadol and Celecoxib effective pain control for hysteroscopy

Use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain not linked with adverse outcomes in high risk groups

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

2 Minute Medicine Rewind October 15, 2018

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Childhood maltreatment may cause mental health problems
  • #VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
  • Metformin use may decrease risk of osteoarthritis development
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options